Edward Miller

The refusal to sell was motivated by a desire to maximize GSK's profits, and GSK had not shown that not having these profits would prejudice consumers by restricting GSK's R&D.

European court's "return to common sense" on parallel trade set to save big pharma 3.5 billion euros...